Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Down 5.40%
As of Thursday, November 12, Trevi Therapeutics, Inc.’s TRVI share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Michael Rose
Cynthia McLaughlin
| Share Statistics | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,902.8 | $421.5 | 55% |
|
| Shares Out (Mil) | 159.7 | 46.9 | 71% |
|
| Institutional Ownership | 99.3% | 82.0% | 86% |
|
| Float (Mil) | 118.8 | 49.2 | 64% |
|
| Beta | 1.12 | 0.68 | 66% |
|
| Avg Daily Volume (000s) | 1,821 | 347 | 79% |
|
| Price Change (52-week) |
20.9% | 49.3% | 73% |
|
| Growth | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (5.5%) | (1.3%) | 34% |
|
| EPS (5yr) | 29.5% | 15.1% | 81 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 30.5% | (15.0%) | 86% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.149) | ($0.484) | ($0.607) | |
| Month Ago EPS | ($0.143) | ($0.479) | ($0.577) | |
| # Rev Up | 1 | 2 | 2 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.143) | ($0.479) | ($0.577) | |
| Year/Year Chg | 11.2% | 52.7% | 118.9% | |
| Financials | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($61) | ($11) | 14% |
|
| EPS (TTM) | ($0.400) | ($0.700) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($7) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($29) | $1 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $1,826 | $331 | 48% |
|
| Valuation | TRVI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.30 | 2.08 | 87% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (23.8%) | (23.8%) | 18% |
|
| ROE | (24.7%) | (24.2%) | 22% |
|
| Liabilities to Assets | 2.6% | 31.6% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Trevi Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors